Skip to main content

Table 2 Parameter estimates for meropenem from the final covariate two-compartment population pharmacokinetic model

From: Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study

Parameter

ACLF

NLF

p

Structural pharmacokinetic parameters for meropenem (RSE, %)

CL [L/h]

5.06 (6.70)

ns

V1 [L]

8.31a

n/a

V2 [L]

35.5 (33.3)

18.5 (33.2)

0.05

Q [L/h]

7.23 (9.80)

n/a

Interindividual variability parameters for meropenem (RSE, %)

CL, CV [%]

29.8 (16.8)

n/a

Q, CV [%]

27.6 (28.8)

n/a

Residual variability parameter σ proportional, CV %

22.0 (8.40)

n/a

  1. RSE is presented on the approximated standard deviation scale
  2. ACLF acute-on-chronic liver failure, NLF patients without liver failure, CL clearance, V1/2 central/peripheral volume of distribution, Q intercompartmental clearance, CV coefficient of variation, ns not statistically significant, n/a not applicable, RSE relative standard error
  3. aValue fixed (see “Methods” section)